Adults

For adults and adolescents 15 years and older, the recommended dose is one 10 mg tablet daily, taken in the evening. (Note: This specific product is 5mg, so it's primarily for children as per typical Montelukast dosing guidelines for 5mg ODT)

Elderly

No dosage adjustment is generally required for elderly patients.

Renal_impairment

No dosage adjustment is necessary for patients with renal impairment.

Children_6_14_years

For pediatric patients 6 to 14 years of age, the recommended dose is one 5 mg ODT tablet daily, taken in the evening.

Onset

Clinical improvement typically seen within 1 day for chronic asthma and allergic rhinitis. For exercise-induced bronchoconstriction, protection is observed within 2 hours after a single dose.

Excretion

Primarily excreted in the feces via bile (approximately 86% of the dose within 5 days). Less than 0.2% is excreted in the urine.

Half life

Plasma half-life ranges from 2.7 to 5.5 hours.

Absorption

Rapidly absorbed after oral administration. Peak plasma concentration (Tmax) achieved in approximately 2-4 hours. Bioavailability is about 64%.

Metabolism

Extensively metabolized in the liver, primarily by cytochrome P450 enzymes CYP3A4, CYP2C9, and CYP2C8.

Rifampin

Coadministration with rifampin, a potent inducer of CYP3A4, CYP2C8, and CYP2C9, significantly decreases the plasma concentration of montelukast. Clinical monitoring is advised.

Phenobarbital

Coadministration with phenobarbital may decrease the area under the plasma concentration-time curve (AUC) of montelukast by approximately 40%, indicating that a dosage adjustment of montelukast may be necessary.